BVT-0204-M0011 mgCHF 250.00
BVT-0204-M0055 mgCHF 750.00
|Source/Host Chemicals||Isolated from Actinomyces sp. Gö301.|
|Purity Chemicals||≥98% (HPLC)|
|Solubility||Soluble in DMSO or methanol.|
|Identity||Determined by 1H-NMR.|
|Declaration||Manufactured by BioViotica.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
Stable for at least 1 year after receipt when stored at -20°C.
After reconstitution protect from light at -20°C.
|Product Specification Sheet|
- Antibiotic against Gram-positive bacteria, particularly Staphylococcus and Clostridia.
- More effective against multi-resistant strains (MRSA) than erythromycin and vancomycin.
- Inhibits cell proliferation and induces HL-60 cell differentiation in combination with 1,25-Dihydroxyvitamin-D3 and ATRA.
- Displays low cytotoxicity compared to erythromycin and spiramycin.
- Structure of natural antibiotic CP-47,444: W.D. Celmer et al., J. Am. Chem. Soc. 102, 4203 (1980)
- 9-O-Esters of nodusmicin: B.J. Magerlein and S.A. Mizsak, J. Antibiot. 35, 111 (1981)
- Biosynthetic origin of the carbon skeleton and oxygen atoms of nargenicin A1: D.E. Cane and C. Yang, J. Am. Chem. Soc. 106, 784 (1984)
- Biosynthesis of nargenicin and nodusmicin: W.C. Snyder and K.L. Rinehart, jr., J. Am. Chem. Soc. 106, 787 (1984)
- Nargenicin biosynthesis: D.E. Cane et al., J. Am. Chem. Soc. 115, 527 (1993)
- The chemistry of the Nargenicin macrolides: J. Kallmerten, in Studies in natural products chemistry (Ed.: A.-U. Rahman, Elsevier) 17, 283 (1995)
- Production, isolation and biological activity of nargenicin from Nocardia sp. CS682: J.K. Sohng et al., Arch. Pharm. Res. 31, 1339 (2008)
- Quantitative analysis of nargenicin in Nocardia sp. CS682 culture by HPLC: S.S. Cho et al., Arch. Pharm. Res. 32, 335 (2009)
- Nargenicin attenuates lipopolysaccharide-induced responses in BV-2 cells: J.C. Yoo et al., Neuroreport 20, 1007 (2009)
- Nargenicin enhances 1,25-dihydroxyvitamin D3- and all-trans retinoic acid-induced leukemia cell differentiation via PKCbetal/MAPK pathways: S.H. Kim et al., Biochemical Pharmacology 77, 1694 (2009)
- Enhanced production of nargenicin A1 and generation of novel glycosylated derivatives: D. Dhakal, et al.; Appl. Biochem. Biotechnol. 175, 2934 (2015)